WO2021122906A1 - Composés anthelminthiques comprenant une structure d'azaindoles - Google Patents

Composés anthelminthiques comprenant une structure d'azaindoles Download PDF

Info

Publication number
WO2021122906A1
WO2021122906A1 PCT/EP2020/086660 EP2020086660W WO2021122906A1 WO 2021122906 A1 WO2021122906 A1 WO 2021122906A1 EP 2020086660 W EP2020086660 W EP 2020086660W WO 2021122906 A1 WO2021122906 A1 WO 2021122906A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
alkoxy
independently selected
group
Prior art date
Application number
PCT/EP2020/086660
Other languages
English (en)
Inventor
Michael Berger
Michael Linder
Carolin SCHNEIDER
Janina TÄNZLER
Ulrich Sondern
Original Assignee
Intervet International B.V.
Intervet Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V., Intervet Inc. filed Critical Intervet International B.V.
Priority to BR112022012130A priority Critical patent/BR112022012130A2/pt
Priority to JP2022537141A priority patent/JP2023506303A/ja
Priority to CN202080088930.0A priority patent/CN114846014A/zh
Priority to US17/785,646 priority patent/US20230110397A1/en
Priority to EP20833809.5A priority patent/EP4077322A1/fr
Priority to CA3164104A priority patent/CA3164104A1/fr
Priority to AU2020404100A priority patent/AU2020404100A1/en
Priority to MX2022007671A priority patent/MX2022007671A/es
Publication of WO2021122906A1 publication Critical patent/WO2021122906A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P5/00—Nematocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria , in particular Dirofilaria immitis.
  • helminths can be categorized in the following groups of a) cestodes: e.g. Anaplocephala spp.; Dipylidium spp.; Diphyllobothrium spp.; Echinococcus spp.; Moniezia spp.; Taenia spp.; b) trematodes e.g. Dicrocoelium spp.; Fasciola spp.; Paramphistomum spp.; Schistosoma spp.; or c) nematodes, e.g.
  • cestodes e.g. Anaplocephala spp.; Dipylidium spp.; Diphyllobothrium spp.; Echinococcus spp.; Moniezia spp.; Taenia spp.
  • trematodes e.g. Dicrocoelium spp.; Fasciola spp.; Paramphistomum
  • Necator spp. Nematodirus spp.; Nippostrongylus spp.; Oesophagostomum spp.; Onchocerca spp.; Onchocercidae spp; Ostertagia spp.; Oxyuris spp.; Par ascaris spp.; Stephanurus spp.; Strongylus spp.; Syngamus spp.; Toxocara spp.; Strongyloides spp.; Teladorsagia spp.; Toxascaris spp.; Trichinella spp.; Trichuris spp.; Trichostrongylus spp.; Triodontophorous spp.; Uncinaria spp., and/or Wuchereria spp.
  • helminthiasis also known as worm infection.
  • These helminths often live in the gastrointestinal tract of their host, but they may also burrow into other organs, where they induce physiological damage.
  • Ascaridia spp. are reported to cause from infections of the small intestine to partial or even total obstruction of the gastrointestinal tract of the affected animal, in particular feather animals such as birds.
  • Haemonchus spp. are known to affect animals like sheep and goats, wherein such infestation often results in the attachment in the abomasal mucosa for sucking blood from the host.
  • the affected animal can get anaemic and short of breath.
  • Oesophagostomum spp. are known to cause a nodule formation in the intestines of its infected hosts, which may result in dysentery.
  • heartworm disease also known as cardiovascular dirofilariasis
  • cardiovascular dirofilariasis is a serious and mostly fatal disease that may affect inner organs such as lung and heart in pets and certain mammals.
  • the disease is caused by parasitic nematodes, Dirofilaria immitis , which in the adult state can have a length up to about 30 centimetres and a thickness of about 1 millimetre.
  • These nematodes live in the heart, the lung and associated blood vessels causing severe lung disease, heart failure and damage to other inner organs such as the liver and kidneys.
  • heartworm infection may result in complication for the host, typically culminating in the host’s death.
  • the heartworm disease is known to affect pets, in particular dogs, which are considered as the definitive host. However, also cats, ferrets, wolves, coyotes, jackals, foxes, bears, sea lions and in very rare cases even humans (zoonosis) may be affected by heartworms.
  • Heartworms have to go through different stages before they become adults residing in the host animal.
  • the mosquito plays an essential role in the heartworm’s life cycle since it is required as an intermediate host.
  • Adult female heartworms living in an infected host give birth to larvae called microfilaria, which can circulate in the bloodstream for as long as two years and are ingested by bloodsucking mosquitos.
  • microfilaria which can circulate in the bloodstream for as long as two years and are ingested by bloodsucking mosquitos.
  • a mosquito bites and takes up blood from such an infected host it picks up said microfilaria, which start to develop in the mosquito such that the first and second larval stages (Li) and (L 2 ) of the heartworm development occurs within the body of a mosquito.
  • the larvae become immature adults (fifth larval stage; L 5 ,) and between 75 and 120 days after infection (bite of the mosquito), these immature heartworms then enter the bloodstream and are carried to the heart and the pulmonary system, where they significantly increase in size over the next about three months.
  • the adult worms have mated, and the females begin giving birth to the above-mentioned microfilaria.
  • the matured heartworms can live for up to about 7 years in dogs and up to about 3 years in cats. Due to the longevity of these worms, each mosquito season can lead to an increasing number of heartworms in an infected pet.
  • WO 2017/178416 discloses a compound considered as anthelmintic, namely a pyrazolopyrimidine derivative of the following structure wherein residues R 1 , R 2 , R 3 , R 4 , Q, X and Y are defined correspondingly.
  • the molecules are considered as modulators of the calcium-activated potassium channel slo-lof nematodes, wherein slo-1 can be regarded as the helminth’s ortholog of the human KCal .1 channel (potassium calcium-activated channel subfamily M alpha 1), which is encoded by the KCNMA1 gene (KCal.l and KCNMA1 are often used synonymously). Slo-1 exhibits calcium-activated potassium channel activity and voltage-gated potassium channel activity. Slo-1 channels play an important role in the neuromuscular system as well as in secretory cells among others. Thus, slo-1 modulators are reported to be involved in several processes including behavioural response to ethanol, locomotion and pharyngeal pumping. More particularly they disrupt neuromuscular transmission causing a flaccid paralysis and also affect feeding and egg-laying. Further, they slow the development of the larvae and the adults of the corresponding helminth.
  • new anthelmintic compounds which can be used to address infections in mammals by parasitic helminths such as Ostertagia ostertagi, Cooperia oncophora, Cooperia punctata, Trichostrongylus axei, Haemonchus placei, Haemonchus contortus, Nematodirus helvetianus, Nematodirus spathiger, Trichostrongylus colubriformis, Trichostrongylus circumcincta, Oesophagostomum venulosum, Chabertia ovina, Dictyocaulus viviparous, Dictyocaulus filaria, Dirofilaria immitis, Dirofilaria repens; b) Trematodes: Fasciola hepatica, Fascioloides
  • Another object is to provide new anthelmintic compounds which can be used to address infections in mammals, wherein these compounds are compatible with standard antiparasitic treatments in pets, in particular in cats and dogs, especially in dogs.
  • anthelmintic compounds which can be used to address infections in mammals by parasitic helminths, in particular infections by Dirofilaria immitis (heartworm), but does not negatively affect the host by undesired side-effects.
  • said new anthelmintic compounds can be used in different treatment schedules, in particular in monthly or longer treatment schedules.
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-io-cycloalkyl, 5- to 10- membered heterocyclyl, C 6 -io-aryl, 5- to 10- membered heteroaryl, Ci- 6 -alkoxy-Ci- 6-alkyl, Ci- 6 -alkyl substituted with C3-io-cycloalkyl, Ci- 6 -alkyl substituted with 5- to 10- membered heterocyclyl, Ci- 6 -alkyl substituted with C 6 -io-aryl or Ci- 6 -alkyl substituted with 5- to 10- membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with
  • R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6-alkyl
  • R 2 , R 3 , R 4 ,R 5 and R 6 are independently selected from hydrogen and C 1-6-alkyl
  • R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-io-cycloalkyl, 5- to 10- membered heterocyclyl, C 6 -io-aryl, 5- to 10- membered heteroaryl, Ci- 6 -alkoxy-Ci- 6 -alkyl, Ci- 6 -alkyl substituted with C3-io-cycloalkyl, Ci- 6 -alkyl substituted with 5- to 10- membered heterocyclyl, Ci- 6 -alkyl substituted with C 6 -io-aryl, Ci- 6 -alkyl substituted with 5- to 10- membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-io-cycloalkyl, 5- to 10- membered heterocyclyl, C 6 -io-aryl, 5- to 10- membered heteroaryl, Ci- 6 -alkoxy-Ci- 6-alkyl, Ci- 6 -alkyl substituted with C3-io-cycloalkyl, Ci- 6 -alkyl substituted with 5- to 10- membered heterocyclyl, Ci- 6 -alkyl substituted with C 6 -io-aryl or Ci- 6 -alkyl substituted with 5- to 10- membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 13 is hydrogen or C 1-3 alkyl
  • R 14 is hydrogen, C1-3 alkyl, C1-3 alkoxy, NR 14 R 14 , wherein R 14 and R 14 are independently C1-3- alkyl, or
  • R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 17 R 17 , wherein R 17 and R 17 are independently Ci- 3 -alkyl,
  • R 18 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 18 R 18 , wherein R 18 and R 18 are independently Ci- 3 -alkyl,
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5- to 10- membered heteroaryl, wherein each C 6 -io-aryl or 5- to 10- membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5- to 10- membered heteroaryl, C1-6- alkoxy-C 1-6-alkyl, Ci-C 6 -alkyl substituted with C 6 -io-aryl, Ci- 6 -alkyl substituted with 5- to 10- membered heteroaryl, or R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C2-6-alkenyl, C3-io-cycloalkyl, 5- to 10- membered heterocyclyl, C 6 -io-aryl, 5- to 10- membered heteroaryl, Ci- 6 -alkoxy or Ci- 6
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 20’ , R 21’ , R 22 ,R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 25 is independently selected from hydrogen and Ci- 6 -alkyl, or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug and mixtures thereof.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C 3 -io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein each Ci- 6 -alkyl or Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6 -alkyl, C 3 -io-cycloalkyl, C 6 -io-aryl, 5- to 10 membered heterocyclyl and 5- to 10 membered heteroaryl, or R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5- to 10 membered heterocyclyl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl, and 5- to 10 membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci- 6 -alkyl, Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ;
  • R 10 , R 11 and R 12 are independently selected from hydrogen or Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen or Ci- 6 -alkyl.
  • R 8 are R 9 are independently selected from hydrogen or Ci- 6 -alkyl.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl.
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl, R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 19 is independently selected from the group consisting of
  • each C 6 -io-aryl or 5- to 10- membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each C 1-6-alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and C 1-6-alkyl.
  • R 19 is independently selected from the group consisting of
  • each C 6 -io-aryl or 5- to 10- membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and Ci- 6 -alkyl .
  • R 19 is independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, halogen, cyano, nitro and hydroxy.
  • R 19 is C 6 -io-aryl, wherein the C 6 -io-aryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci- 6 -alkyl, halogen, cyano and nitro.
  • R 19 is C 6 -io-aryl, wherein the C 6 -io-aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 25 is hydrogen
  • the compound according to Formula (I) is present in form of the fV)-enantiomer
  • the present invention provides a process for preparing the compound according to Formula (I) comprising the step of reacting a compound of Formula (A) with a compound of Formula (B)
  • Hal is a halogen
  • R 1 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are defined as in any one of claims 1 to 13, to obtain the compound according to Formula (I).
  • the present invention provides a veterinary composition
  • a veterinary composition comprising compound according to Formula (I), and one or more physiologically acceptable excipient(s).
  • the one or more physiologically acceptable excipient(s) are selected from carriers, fillers, flavours, binders, antioxidants, buffers, sugar components, lubricants, surfactants, stabilizers, flow agents, disintegration agents and preservatives and mixtures thereof.
  • the present invention provides compounds according to Formula (I) or the veterinary composition according to the invention for use as a medicament.
  • the present invention provides compounds according to Formula (I) or the veterinary composition according to the invention for use in the treatment of disorders/diseases caused by helminths.
  • the disease is filariasis and in particular heartworm disease.
  • the helminths are Dirofilaria immitis.
  • the compounds according to the invention and/or any embodiments thereof are useful in the treatment of helminth infection such as filariasis and in particular heartworm disease.
  • the compounds according to the invention and/or any embodiments thereof are useful in the treatment of the disorders/diseases caused by helminths such as nematodes, in particular Dirofilaria immitis , wherein the disorder/disease caused by Dirofilaria immitis is the heartworm disease.
  • the compounds according to the invention and/or any embodiments thereof are effective against helminth such as Dirofilaria immitis , but not effective against bacteria that are especially relevant in the mammal’s, in particular the dog’s, health, such as Acinetobacter baumanii or Staphylococcus spp. or Streptococcus spp.
  • helminth such as Dirofilaria immitis
  • bacteria that are especially relevant in the mammal’s, in particular the dog’s
  • health such as Acinetobacter baumanii or Staphylococcus spp. or Streptococcus spp.
  • reference to a certain element is meant to include all isotopes of that element.
  • a group is defined to include hydrogen or a residue is hydrogen, it also includes deuterium and tritium.
  • Ci- 6 -alkyl refers to alkyl groups having 1 to 6 carbon atoms that do not contain heteroatoms. Thus, the term includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl and hexyl.
  • the term also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following that are provided by way of example: -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH( CH 2 CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , -CH(CH 3 )CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 C(CH 3 ) 3 and others.
  • the term “Ci- 6 -alkyT includes primary alkyl groups having 1 to 6 carbon atoms, secondary alkyl groups having 3 to 6 carbon atoms and tertiary alkyl groups having 4 to 6 carbon
  • Ci- 3 -alkyl refers to alkyl groups having 1 to 3 carbon atoms that do not contain heteroatoms.
  • the term includes straight chain alkyl groups such as methyl, ethyl, and propyl.
  • the term also includes branched chain isomers of straight chain alkyl groups, namely CH(CH 3 ) 2 .
  • the term “Ci- 3 -alkyT includes primary alkyl groups having 1 to 3 carbon atoms, and a secondary alkyl groups having 3 carbon atoms.
  • C 2-6 -alkynyl refers to straight and branched chain alkynyl groups such as those described with respect to the “C 2-6 -alkyl” defined above, except that at least one triple bond exists between two carbon atoms.
  • Examples include, but are not limited to, - to-CoCH, -CoCCH 3 , -CoC- CH 2 CH 3 , -CH 2 -CoCH, -CH(CH 3 )-CoCH, -C(CH 3 ) 2 -CoCH, -CH 2 -CoCCH 3 , -CH(CH 3 )-CoCCH 3 , -C(CH )2-CoCCH3 , -CH 2 -CoC-CH 2 CH 3 , -CH(CH 3 )-CoC-CH 2 CH3, -C(CH 3 ) 2 -CoC- CH 2 CH 3 , -(CH 2 ) 2 - CoC-CH 2 CH 3 , -(CH 2 ) 3 - CoC-CH 3 among others.
  • C 3 -io-cycloalkyl refers to non-aromatic monocyclic alkyl groups having 3 to 10 carbon atoms or non-aromatic polycyclic alkyl groups having 3 to 10 carbons atoms, wherein said groups consist solely of carbon and hydrogen atoms. Cycloalkyl may include fused or bridged ring systems having 3 to 10 carbon atoms. Non-aromatic monocyclic alkyl groups having 3 to 10 carbon atoms include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptly, cyclooctyl and the like.
  • Non-aromatic polycyclic alkyl groups having 3 to 10 carbon atoms include, but are not limited to, adamantine, norbomane, decalinyl, 7,7-dimethyl- bicyclo[2.2.1]heptanyl and the like.
  • 5- to 10-membered heterocyclyl refers to cyclic groups wherein 5 to 10 members (atoms) form the skeleton, wherein the skeleton of said cyclic compounds comprises at least one carbon atom and at least one heteroatom.
  • heteroatoms include, but are not limited to, N, O and S.
  • the “5 to 10-membered heterocyclyl” may be a monocyclic, bicyclic or polycyclic group which may include fused or bridged ring systems, wherein a part of the fused ring system may be aromatic; the nitrogen, carbon or sulphur atoms in the “5 to 10-membered heterocyclyl” may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl residue radical may be partially saturated.
  • heterocyclyl groups include, but are not limited, to pyrrolinyl, 3H-pyrazolyl, 4H- pyrazolyl dihydropyridyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, homopiperazinyl, indolinyl, quinuclidinyl, morpholinyl, thiomorpholinyl thiazolodinyl, dihydrodithiinyl, dihydrodithionyl, tetrahydrothiophene, tetrahydrothiopyran, benzothiazinyl such as 2H-1,4- benzothiazinyl, dihydrobenzothiazinyl such a 2H-3,4-dihydrobenzothiazinyl, benzodioxolyl such as 1, 3-benzodioxoyl, dihydrooxathiinyl, 1,4-oxathia
  • heterocyclyl groups include, but are not limited to, those described above in which one or more S atoms in the ring is double-bonded to one or two oxygen atoms (sulfoxides and sulfones) such as tetrahydrothiophene, tetrahydrothiophene oxide and tetrahydrothiophene-l,l-dioxid as well as thiomorpholine, thiomorpholine oxide and thiomorpholine -1,1 dioxiide.
  • oxygen atoms sulfoxides and sulfones
  • C 6-10 aryl refers to a group with an aromatic skeletal structure, wherein the ring atoms of the aromatic skeletal structure are carbon atoms.
  • the"C 6 -io aryl does not contain heteroatoms such as N, S, O in the aromatic skeletal structure.
  • aryl groups include, but are not limited, to phenyl, biphenyl and naphthyl.
  • the term "5 to 10-membered heteroaryl” refers to an aromatic group wherein 5 to 10 members (atoms) form the skeleton, wherein the skeleton of said cyclic compound comprises at least one carbon atom and at least one heteroatom.
  • heteroatoms include, but are not limited to, N, O and S.
  • the “5 to 10-membered heterocyclyl” may be a monocyclic or bicyclic or polycyclic group, which may include fused ring systems.
  • Examples of 5 to 10-membered heteroaryl groups include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl such as 1H- 1,2,3- triazolyl, 2H-l,2,3-triazolyl,lH-l,2,4-triazolyl and 4H-l,2,4-triazlyl, tetrazolyl such as lH-tetrazolyl, 2H tetrazolyl and 5H-tetrazoyl, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, naphthyridinyl, benzotriazolyl, oxazolyl, isoxazolyl, oxadiazol
  • Ci- 6 -alkoxy refers to a group which based on an alkyl group having 1 to 6 carbon atoms bound to an oxygen.
  • the alkyl group having 1 to 6 carbon atoms refers to straight and branched chains such as those described with respect to the “Ci- 6 -alkyl” defined above.
  • Ci-3-alkoxy refers to a group which is based on an alkyl group having 1 to 3 carbon atoms bound to an oxygen.
  • the alkyl group having 1 to 3 carbon atoms refers to straight and branched chains such as those described with respect to the “Ci-3-alkyl” defined above.
  • Ci- 6 -alkylmercapto refers to a group which is based on an alkyl group having 1 to 6 carbon atoms bound to a sulfur
  • the alkyl group having 1 to 6 carbon atoms refers to straight and branched chains such as those described with respect to the “Ci- 6 -alkyl” defined above.
  • Optionally substituted refers to the optional replacement of one or more hydrogen(s) of the group to be substituted with one or more of the defined substituent(s).
  • protecting groups may be protected.
  • protected refers to forms of these functionalities with a protecting group to prevent said groups from undesirable reaction.
  • protecting groups are known to those skilled in the art for example from Protective Groups in Organic Synthesis; Wuts, P. G. M. John Wiley & Sons, New York, NY, (53 th Edition, 2014).
  • the protecting groups can be added or removed using the procedures set forth therein.
  • Examples of protected hydroxyl groups include, but are not limited to, silyl ethers such as those obtained by reaction of a hydroxyl group with a reagent such as, but not limited to, t-butyldimethyl- chlorosilane, trimethylchlorosilane, triisopropylchlorosilane, triethylchlorosilane; substituted methyl and ethyl ethers such as, but not limited to, methoxymethyl ether, methythiomethyl ether, benzyloxymethyl ether, t-butoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ethers, 1 -ethoxy ethyl ether, allyl ether, benzyl ether; esters such as, but not limited to, benzoylformate, formate, acetate, trichloroacetate and trifluoracetate.
  • a reagent such as, but not
  • protected amine groups include, but are not limited to, amides such as formamide, acetamide, trifluoroacetamide and benzamide; imides, such as phthalimide and dithiosuccinimide; carbamate such as tert-butyloxycarbonyl (Boc) and others.
  • protected mercapto groups include, but are not limited to, thioether such as S-benzyl thioether, and S-4-picolyl thioether; substituted S-methyl derivatives such as hemithio, dithio and aminothio acetals and others.
  • Stereoisomers include compounds which are made of the same atoms connected in the same sequence, but the atoms are positioned differently in space. Stereoisomers include diastereoisomers and enantiomers.
  • a “physiologically acceptable salt” it referred to as salt with an inorganic base, organic base, inorganic acid, organic acid or basic or acidic amino acid.
  • suitable inorganic acids for making (physiologically acceptable) salts include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • suitable organic acids for making (pharmaceutically acceptable) salts include, but are not limited to, cholic acid, sorbic acid, lauric acid, acetic acid, trifluoroacetic acid, formic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, digluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, mesylic acid, stearic acid, salicylic acid, p-hydroxybenzoic acid, phenylacetic acid, mandelic acid, embonic acid, ethanesulfonic acid, benzenesulfonic acid, toluene sulfonic acid, pantothenic acid, 2-hydroxyethanesulfonic acid, sulfanilic acid, cyclohexylaminosul
  • base addition salts may include, for example, metallic salts and organic salts.
  • Metallic salts include, but are not limited to, alkali metal (group la) salts, alkaline earth metal (group Ila) salts and other physiologically acceptable metal salts.
  • alkali metal (group la) salts alkaline earth metal (group Ila) salts and other physiologically acceptable metal salts.
  • such salts may be made from aluminium, calcium, lithium, magnesium, potassium, sodium, and zinc.
  • a free acid compound may be mixed with sodium hydroxide to form such a base addition salt.
  • Organic salts may be made from amines, such as trimethylamine, diethylamine, N, N' -dibenzyl - ethylenediamine, chloroprocaine, ethanolamine, diethanolamine, ethylenediamine, N-methyl- glucamine, procaine and basic amino acids such as arginine, lysine and ornithine.
  • amines such as trimethylamine, diethylamine, N, N' -dibenzyl - ethylenediamine, chloroprocaine, ethanolamine, diethanolamine, ethylenediamine, N-methyl- glucamine, procaine and basic amino acids such as arginine, lysine and ornithine.
  • ester refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
  • Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
  • Representative examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethyl succinates.
  • a solvate of a compound can be regarded as a compound in which an organic solvent or water adheres to said compound.
  • Organic solvents refer to the ones which are known by the skilled person. In case that water is adhered to the compound the corresponding compound is known as a hydrate.
  • polymorph as used herein and as generally understood by the skilled person refers to different crystalline forms of the same molecular entity. Therefore, due to their different chemical compositions, solvates and hydrates as discussed above are not included in the definition of polymorphism but are rather designated “pseudopolymorphs” instead.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above Formula ((I), for example by hydrolysis in blood.
  • a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
  • prodrugs refers to those prodrugs of the compounds of the present invention that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 is defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and C 1-3 -alkyl.
  • R 5 and R 6 are independently selected from hydrogen and C 1-3 -alkyl
  • R 2, and R 3 ’ are independently selected from hydrogen and Ci- 3 -alkyl.
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6 -alkyl, Ci-6-alkoxy and halogen, wherein Ci-6-alkyl and Ci-6-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci- 3 -alkyl, more preferably from hydrogen and methyl.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride.
  • the compounds are according to Formula (Iai), (Iaii) or (Iaiii). or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug and mixtures thereof, wherein R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are defined as in any of the embodiments described herein.
  • the compounds are according to Formula (Iai), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iaii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iaiii), preferably in form of the fV)-enantiomer
  • R 7 is defined as above.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 10 , R 11 and R 12 are independently selected from hydrogen or Ci- 6 -alkyl, preferably from hydrogen or Ci-3-alkyl,
  • R 8 , R 9 , R 10 ,R U and R 12 are independently selected from hydrogen or Ci- 6 -alkyl, preferably from hydrogen or C 1.3 -alkyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci- 6 -alkyl, preferably from hydrogen or Ci-3-alkyl.
  • R 7 is independently selected from the group consisting of hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, 4 to 10-membered heterocyclyl, Ci- 3 -alkoxy, hydroxy,
  • each C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the C 1-6-alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci- 3 -alkyl, preferably from hydrogen, methyl or ethyl.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, preferably dimethylamino and morpholin-4-yl.
  • the compounds are according to Formula (Ibi), (Ibii), (Ibiii), (Ibiv), (Ibv), (Ibvi), (Ibvii), (Ibvii), (Ibix), (Ibx) or (Ibxi)
  • R 1 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are defined as in any of the embodiments described herein.
  • the compounds are according to Formula (Ibi), preferably in form of the fY)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ibii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ibiii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ibiv), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ibv), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ibvi), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ibvii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ibviii), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Ibix), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ibx), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ibxi), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 13 and R 14 as well as R 15 , R 16 , R 17 and R 18 are defined as above.
  • R 13 is hydrogen or C 1-3 alkyl
  • R 14 is hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 13 is hydrogen or C 1-3 alkyl
  • R 14 is hydrogen or C 1-3 alkyl
  • R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl
  • R 14 is hydrogen or methyl, preferably hydrogen.
  • R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 13 is hydrogen or Ci- 3 -alkyl
  • R 14 is hydrogen, Ci- 3 -alkyl, or Ci- 3 -alkoxy,
  • R 15 is hydrogen, halogen, Ci- 3 -alkyl, Ci- 3 -alkoxy, or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is hydrogen, halogen, Ci- 3 -alkyl, Ci- 3 -alkoxy, or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is hydrogen or Ci- 3 -alkyl
  • R 18 is hydrogen or Ci- 3 -alkyl.
  • R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl
  • R 14 is hydrogen or methyl, preferably hydrogen
  • R 15 is hydrogen or C 1-3 alkyl, preferably hydrogen or methyl
  • R 16 hydrogen or C 1-3 alkyl, preferably hydrogen or methyl
  • R 17 and R 18 are hydrogen.
  • R 13 is hydrogen, methyl or ethyl, preferably hydrogen or methyl
  • R 14 is hydrogen or methyl, preferably hydrogen
  • R 15 , R 16 , R 17 and R 18 are hydrogen.
  • the compounds are according to Formula (Ic).
  • the compounds are according to Formula (Ic), preferably in form of the fV)-enantiomer
  • . - denotes the bond to the amide group
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Idi), (Idii), (Idiii) or (Idiv).
  • the compounds are according to Formula (Idi), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Idii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Idiii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Idiv), preferably in form of the fV)-enantiomer
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl, or C 1-3 alkoxy.
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Idv), (Idvi) or (Idvii)
  • the compounds are according to Formula (Idv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Idvi), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Idvii), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 19 is defined as above.
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 19 is independently selected from the group consisting of
  • each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-alkyl.
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C6-io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci-6-alkyl, preferably from hydrogen and C 1.3 -alkyl.
  • R 19 is independently selected from the group consisting of C6-io-aryl and 5 to 10-membered heteroaryl wherein each C6-io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci-6-alkyl Ci-6-alkoxy, halogen, cyano, nitro and hydroxy.
  • R 19 is a 5 to 10-membered heteroaryl wherein the 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci-6-alkyl Ci-6-alkoxy, halogen, cyano, nitro and hydroxy.
  • R 19 is a 5 to 10-membered heteroaryl wherein the 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci-6-alkyl and halogen preferably halogen.
  • Examples of 5 to 10-membered heteroaryl groups include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrimidin-4-yl, pyrazinyl, pyridazinyl, triazolyl such as lH-l,2,3-triazolyl, 2H-l,2,3-triazolyl,lH- 1,2,4-triazolyl and 4H-l,2,4-triazlyl, tetrazolyl such as lH-tetrazolyl, 2H tetrazolyl and 5H- tetrazoyl, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinoline 4-yl, quinoline
  • R 19 is a 5 to 10-membered heteroaryl, wherein the 5 to 10-membered heteroaryl is substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl and halogen preferably halogen.
  • R 19 is C 6 -io-aryl, wherein the C6-10 aryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl halogen, cyano and nitro.
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide include, but are not limited to, 2-fluoro- phenyl, 3-fluourophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- bromophenyl, 3-bromophenyl, 4-bromophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-di- fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,6-difluorophenyl, 2,3-dichlorophenyl,
  • 3-flurorophenyl 3-chlorophenyl, 2,3-diflurorophenyl, 3,5-difluorophenyl, 2,3-di- chlorophenyl, 2,6-difluorophenyl, 3,5-dichlorophenyl, 2-chloro-3 -fluorophenyl, 3-chloro-2- fluorophenyl, 5-chloro-3-fluorophenyl, 5 -chi or-3 -fluorophenyl, 5-chloro-2-fluorophenyl, 3,4,5- trifluorophenyl, 2,3,5-trifluorophenyl, 3,5-dichloro-4-fluorophenyl and 3,4,5-trichlorophenyl, more preferably 2,3-diflurorophenyl, 2,6-difluorophenyl, 3,5-difluorophenyl, 2,3,5- trifluorophenyl, 2-chloro-3 -fluor
  • the compounds are according to Formula (lei), (Ieii), (Ieiii), (Ieiv), (lev), (Ievi), (Ievii), (Ieviii), (Ieix) or (lex) Formula (Ieii)
  • the compounds are according to Formula (lei), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ieii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ieiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ieiv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (lev), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ievi), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ievii), preferably in form of the S)-enantiomer.
  • the compounds are according to Formula (Ieviii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ieix), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (lex), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 25 is defined as above.
  • R 25 is hydrogen or methyl
  • R 25 is hydrogen.
  • the compounds are according to Formula (If)
  • the compounds are according to Formula (If), preferably in form of the S)-enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 and R 7 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6-alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 7 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl, Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ; R 8 and R 9 are independently selected from hydrogen or Ci- 3 -alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci- 3 -alkyl, preferably from hydrogen, methyl or ethyl.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl.
  • the compounds are according to Formula (Igi), (Igii), (Igiii), or (Igiv)
  • the compounds are according to Formula (Igi), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Igii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Igiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Igiv), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 as well as R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci- 6 -alkyl, Ci- 6 - alkoxy, halogen, cyano, hydroxy and NR 2, R 3 ’,
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Ihi), (Ihii) (Ihiii), (Ihiv), (Ihv) or (Ihvi)
  • the compounds are according to Formula (Ihi), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Ihii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ihiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ihiv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ihv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ihvi), preferably in form of the fV)-enantiomer
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci-6-alkyl, C 3 -io-cycloalkyl, C6-io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci-6-alkyl C 3 -io-cycloalkyl and Ci-6-alkoxy
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci-6-alkyl, preferably from hydrogen and Ci- 3 -alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci-6-alkyl, preferably from hydrogen and Ci- 3 -alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6 -alkyl, Ci-6-alkoxy and halogen, wherein Ci-6-alkyl and Ci-6-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Ihvii), (Ihviii) (Ihix) or (Ihx))
  • the compounds are according to Formula (Ihvii), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Ihviii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ihix), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ihx), preferably in form of the fV)-enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 and R 19 are defined as above.
  • R 1 and R 19 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci-6-alkyl, C3-io-cycloalkyl or C6-io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci-6-alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and Ci-6-alkyl .
  • R 1 is independently selected from the group consisting of hydrogen, Ci-6-alkyl, Ci-6-alkoxy and halogen, wherein Ci-6-alkyl and Ci-6-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 19 is C6-io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 19 is independently selected from the group consisting of
  • the compounds are according to Formula (Iii), (Iiii), (Iiiii), (Iiiv), (Iiv) or (Iivi)
  • the compounds are according to Formula (Iii), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Iiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iiiii).
  • the compounds are according to Formula (Iiiv), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Iiv), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iivi), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 and R 25 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and R 25 is hydrogen or methyl preferably hydrogen.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Iji) or (Ijii)
  • the compounds are according to Formula (Iji), preferably in form of the (/ ⁇ -enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ijii), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 7 as well as R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are defined as above.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci-3-alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 7 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • each C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Iki), (Ikii), (Ikiii), (Ikiv), (Ikv) or (Ikvi)
  • the compounds are according to Formula (Iki), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Ikii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ikiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ikiv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ikv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ikvi), preferably in form of the fV)-enantiomer
  • Ci- 6 -alkyl, C2-6-alkenyl, C3-io-cycloalkyl, 4 to 10-membered heterocyclyl or Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or Ci- 3 -alkoxy.
  • R 7 is independently selected from the group consisting of hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, 4 to 10-membered heterocyclyl, Ci- 3 -alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 8 and R 9 are independently selected from hydrogen or Ci- 3 -alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci- 3 -alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Ikvii), (Ikviii), (Ikix) or (Ikx)
  • the compounds are according to Formula (Ikvii), preferably in form of the (/ ⁇ -enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ikviii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ikix), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ikx), preferably in form of the fV)-enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 7 and R 19 are defined as above.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6-alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and Ci- 6 -alkyl .
  • R 7 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 19 is independently selected from the group consisting of
  • the compounds are according to Formula (Ili), (Ilii), (Iliii), (Iliv), (Ilv) or (Ilvi)
  • the compounds are according to Formula (Ili), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ilii), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Iliii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iliv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ilv).
  • the compounds are according to Formula (Ilvi), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 7 and R 25 are defined as above.
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 7 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and R 25 is hydrogen or methyl, preferably hydrogen.
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Imi) or (Imii)
  • the compounds are according to Formula (Imi), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Imii), preferably in form of the ( ⁇ -enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 13 , R 14 , R 15 , R 16 , R 17 and R 18 as well as R 19 are defined as above.
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 20’ , R 21 , R 22 ,R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • R 19 is independently selected from the group consisting of 2.3-diflurorophenyl, 2,6-dif uorophenyl, 2,3,5-trif uorophenyl, 3-chloro-2-fluorophenyl,
  • the compounds are according to Formula (Ini), (Inii), (Iniii), (Iniv), (Inv), (Invi), (Invii), (Inviii) or (Inix)
  • the compounds are according to Formula (Ini), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Inii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iniii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iniv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Inv), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Invi), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Invii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Inviii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Inix), preferably in form of the fV)-enantiomer In one embodiment of the invention and/or embodiments thereof,
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each C 1-6-alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-alkyl
  • R 20’ , R 21 , R 22 ,R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl.
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy and
  • R 19 is independently selected from the group consisting of
  • the compounds are according to Formula (Inx), (Inxi), (Inxii), (Inxiii), (Inxiv) or (Inxv)
  • the compounds are according to Formula (Inx), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Inxi), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Inxii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Inxiii), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Inxiv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Inxv), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 13 , R 14 , R 15 , R 16 , R 17 and R 18 as well as R 25 are defined as above.
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and R 25 is hydrogen or methyl, preferably hydrogen.
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Ioi), (Ioii) or (Ioiii)
  • the compounds are according to Formula (Ioi), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ioii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Ioiii), preferably in form of the fV)-enantiomer
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 ,
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and R 25 is hydrogen or methyl, preferably hydrogen.
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Ioiv) or (Iov)
  • the compounds are according to Formula (Ioiv), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iov), preferably in form of the ( ⁇ -enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 19 and R 25 are defined as above.
  • R 19 is independently selected from the group consisting of
  • each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 20’ , 3 ⁇ 4 21 R 22 R 24 anc [ R 24 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 19 is independently selected from the group consisting of
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Ipi), (Ipii) or (Ipiii)
  • the compounds are according to Formula (Ipi), preferably in form of the ( ⁇ -enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ipii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Ipiii), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 , R 7 as well as R 13 , R 14 , R 15 .
  • R 16 , R 17 and R 18 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci-3-alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci- 3 -alkyl, more preferably from hydrogen and methyl, and
  • R 7 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • each C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci-3-alkyl, 5 to 10-membered heterocyclyl, Ci- 6 -alkoxy, halogen, cyano, hydroxy,
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -O-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-, R 15 is independently hydrogen or C1-3 alkoxy,
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Iqi), (Iqii), (Iqiii), (Iqiv), (Iqv) or (Iqvi)
  • the compounds are according to Formula (Iqi), preferably in form of the ( ⁇ -enantiomer.
  • the compounds are according to Formula (Iqii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqiii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqiv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Iqv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqvi), preferably in form of the fV)-enantiomer
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6-alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 16 is independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci-3-alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci- 3 -alkyl, more preferably from hydrogen and methyl, and
  • R 7 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • each C 1-6-alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing aromatic ring, wherein one or more of the ring-
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • the compounds are according to Formula (Iqvii), (Iqviii), (Iqix) or (Iqx)
  • the compounds are according to Formula (Iqvii), preferably in form of the (/ ⁇ -enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqviii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqix), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Iqx), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 , R 7 and R 19 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O; wherein each Ci- 6 -alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and Ci- 6 -alkyl .
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci- 6 -alkyl, Ci- 6 -alkoxy, halogen, cyano, hydroxy and NR 2 ’R 3 ’,
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 7 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and
  • R 19 is independently selected from the group consisting of
  • the compounds are according to Formula (Iri), (Irii), (Iriii), (Iriv), (Irv) or (Irvi)
  • the compounds are according to Formula (Iri), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Irii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iriii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Iriv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Irv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Irvi), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 , R 7 and R 25 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O wherein the Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl, 5 to 10-membered heterocyclyl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10’ , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl
  • R 8 , R 9 , R 10 , R 11 and R 12 are independently selected from hydrogen and Ci- 6 -alkyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl, Ci- 6 -alkoxy, halogen, cyano, hydroxy and NR 2 ’R 3 ’, R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 7 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl, Ci-3-alkoxy, hydroxy,
  • Ci- 6 -alkyl, C2-6-alkenyl, 4 to 10-membered heterocyclyl or Ci-3-alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 8 and R 9 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein the Ci- 6 -alkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • Ci- 6 -alkyl Ci- 6 -alkoxy, hydroxy and NR 8 R 9 ,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl,
  • R 8 and R 9 are independently selected from hydrogen or Ci-3-alkyl, preferably from hydrogen, methyl or ethyl, and
  • R 25 is hydrogen or methyl, preferably hydrogen.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, isopropenyl, methoxy, ethoxy, isopropoxy, hydroxy, methylmercapto, ethylmercapto, methyl sulfoxyl, methyl sulfonyl, methylthio, amino, methylamino, ethylamino, isopropylamino, dimethylamino, isopropylmethylamino, hydroxy ethylamino, methoxy ethylamino, morpholin-4-yl, 4-methylpiperazin-l-yl, 3- hydroxy-pyrrolidin-l-yl, 3-fluoroazetidinyl and 3,3-difluoroazetidinyl, and R 25 is hydrogen or methyl, preferably hydrogen.
  • the compounds are according to Formula (Isi) or (Isii)
  • the compounds are according to Formula (Isi), preferably in form of the (/ ⁇ -enantiomer.
  • the compounds are according to Formula (Isii), preferably in form of the ( ⁇ -enantiomer.
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 as well as R 19 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 16 is independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci-3-alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each C 1-6-alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and C 1-6-alkyl .
  • R 1 is independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-, -0-, or -S-,
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 13 and R 14 together with the atoms to which they are attached form a 5 or 6- carbon atoms containing non-aromatic ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by -NH-or -0-,
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy
  • R 19 is independently selected from the group consisting of 2,3-diflurorophenyl, 2,6-difluorophenyl, 2,3,5-trifluorophenyl, 3-chloro-2-fluorophenyl,
  • the compounds are according to Formula (Iti), (Itii) (Itiii), (Itiv), (Itv), (Itvi), (Itvii), (Itviii) or (Itix)
  • R 7 and R 25 are defined as in any of the embodiments described herein.
  • the compounds are according to
  • the compounds are according to Formula (Itii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Itiii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Itiv), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Itv), preferably in form of the (ri)-enantiomer.
  • the compounds are according to Formula (Itvi), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Itvii), preferably in form of the fV)-enantiomer
  • the compounds are according to Formula (Itviii, preferably in form of the fV)-enantiomer)
  • the compounds are according to Formula (Itix), preferably in form of the (/ ⁇ -enantiomer.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci- 6 -alkyl, preferably from hydrogen and Ci-3-alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 19 is independently selected from the group consisting of C 6 -io-aryl and 5 to 10-membered heteroaryl, wherein each C 6 -io-aryl or 5 to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-6-alkyl, C3-io-cycloalkyl and C 6 -io-aryl or
  • R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O, wherein each C 1-6-alkyl, C3-io-cycloalkyl or C 6 -io-aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of
  • R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6-alkyl
  • R 23 ’ anc j R 24 ’ are independently selected from hydrogen and C 1-6-alkyl .
  • R 1 is independently selected from the group consisting of hydrogen, C 1-6-alkyl, Ci- 6 -alkoxy and halogen, wherein Ci- 6 -alkyl and Ci- 6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of
  • R 2 ’ and R 3 ’ are independently selected from hydrogen and Ci-3-alkyl, more preferably from hydrogen and methyl, and
  • R 15 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 16 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy
  • R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy and
  • R 19 is C 6 -io-aryl, wherein C6-10 aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.
  • R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride, and
  • R 15 is independently hydrogen or C 1-3 alkoxy
  • R 16 is independently hydrogen or C 1-3 alkoxy
  • R 17 is independently hydrogen or C 1-3 alkoxy
  • R 18 is independently hydrogen or C 1-3 alkoxy.
  • R 19 is independently selected from the group consisting of
  • the compounds are according to Formula (Itx), (Itxi) (Itxii), (Itxiii), (Itxiv) or (Itxv)
  • the compounds are according to Formula (Itx), preferably in form of the fV)-enantiomer. In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Itxi), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Itxii), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Itxiii), preferably in form of the fV)-enantiomer.
  • the compounds are according to Formula (Ixitv), preferably in form of the fV)-enantiomer In an embodiment of the invention and/or embodiments thereof, the compounds are according to Formula (Itxv), preferably in form of the fV)-enantiomer
  • the invention provides a compound according to the invention and/or embodiments thereof, wherein R 1 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 as well as R 25 are defined as above.
  • R 2 and R 3 are independently selected from the group consisting of hydrogen, Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl and 5 to 10-membered heteroaryl, or
  • R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O, wherein each Ci- 6 -alkyl, C3-io-cycloalkyl, C 6 -io-aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of Ci-6-alkyl, C 3 -io-cycloalkyl and Ci-6-alkoxy,
  • R 4 , R 5 and R 6 are independently selected from hydrogen and Ci-6-alkyl, preferably from hydrogen and Ci- 3 -alkyl,
  • R 2 and R 3 are independently selected from hydrogen and Ci-6-alkyl, preferably from hydrogen and Ci- 3 -alkyl, and
  • R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15 R 15 , wherein R 15 and R 15 are independently Ci- 3 -alkyl,
  • R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16 R 16 , wherein R 16 and R 16 are independently Ci- 3 -alkyl,
  • R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés anthelminthiques. Ces composés peuvent par exemple être utilisés dans le traitement du type de maladie de ver provoquée par des helminthes tels que Dirofilaria, en particulier Dirofilaria immitis.
PCT/EP2020/086660 2019-12-18 2020-12-17 Composés anthelminthiques comprenant une structure d'azaindoles WO2021122906A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR112022012130A BR112022012130A2 (pt) 2019-12-18 2020-12-17 Compostos antelmínticos compreendendo uma estrutura azaindólica
JP2022537141A JP2023506303A (ja) 2019-12-18 2020-12-17 アザインドール構造を含む駆虫剤化合物
CN202080088930.0A CN114846014A (zh) 2019-12-18 2020-12-17 包含氮杂吲哚结构的驱虫化合物
US17/785,646 US20230110397A1 (en) 2019-12-18 2020-12-17 Anthelmintic compounds comprising azaindoles structure
EP20833809.5A EP4077322A1 (fr) 2019-12-18 2020-12-17 Composés anthelminthiques comprenant une structure d'azaindoles
CA3164104A CA3164104A1 (fr) 2019-12-18 2020-12-17 Composes anthelminthiques comprenant une structure d'azaindoles
AU2020404100A AU2020404100A1 (en) 2019-12-18 2020-12-17 Anthelmintic compounds comprising azaindoles structure
MX2022007671A MX2022007671A (es) 2019-12-18 2020-12-17 Compuestos antihelminticos que comprenden una estructura de azaindoles.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19217671.7 2019-12-18
EP19217671 2019-12-18
EP20213299.9 2020-12-11
EP20213299 2020-12-11

Publications (1)

Publication Number Publication Date
WO2021122906A1 true WO2021122906A1 (fr) 2021-06-24

Family

ID=74106031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/086660 WO2021122906A1 (fr) 2019-12-18 2020-12-17 Composés anthelminthiques comprenant une structure d'azaindoles

Country Status (9)

Country Link
US (1) US20230110397A1 (fr)
EP (1) EP4077322A1 (fr)
JP (1) JP2023506303A (fr)
CN (1) CN114846014A (fr)
AU (1) AU2020404100A1 (fr)
BR (1) BR112022012130A2 (fr)
CA (1) CA3164104A1 (fr)
MX (1) MX2022007671A (fr)
WO (1) WO2021122906A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2023073641A1 (fr) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Composés de pyrrolopyridazine anthelminthiques
WO2023208174A1 (fr) * 2022-04-28 2023-11-02 杭州普济远成生物医药科技有限公司 Inhibiteur de désubiquitinase et son utilisation
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
US11999742B2 (en) 2022-10-28 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539588A1 (fr) 1990-07-05 1993-05-05 Nippon Soda Co., Ltd. Derive d'amine
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
WO1996029073A1 (fr) 1995-03-20 1996-09-26 Merck & Co., Inc. Derives de l'acide nodulisporique
US5595991A (en) 1995-03-20 1997-01-21 Merck & Co., Inc. Anthelmintic use of nodulisporic acid and analogs thereof
US5834260A (en) 1996-08-30 1998-11-10 Merck & Co., Inc. Antiparasitic agents
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
WO2002085838A1 (fr) 2001-04-24 2002-10-31 Massachusetts Institute Of Technology Formation par catalyse de cuivre de liaisons carbone-heteroatome et carbone-carbone
US20050182059A1 (en) 2003-12-31 2005-08-18 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
US20060128779A1 (en) 2004-11-19 2006-06-15 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1H-pyrrol-2-yl)acrylonitrile derivatives
US20060281695A1 (en) 2005-06-09 2006-12-14 Schering-Plough Animal Health Corporation Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
WO2007115643A1 (fr) 2006-03-31 2007-10-18 Bayer Cropscience Ag Composés énaminocarbonylés substitués
US7312248B2 (en) 2004-09-23 2007-12-25 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
US7361689B2 (en) 2003-12-31 2008-04-22 Schering-Plough Animal Health Corporation Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof
WO2010053517A2 (fr) 2008-10-29 2010-05-14 Aroian Raffi V Polythérapie pour combattre une résistance aux helminthes
WO2010075591A2 (fr) 2008-12-24 2010-07-01 Praxair Technology, Inc. Procédé de réduction des émissions de dioxyde de carbone
WO2017106607A1 (fr) 2015-12-17 2017-06-22 Merck Patent Gmbh Antagonistes de tlr7/8 polycyliques et leur utilisation dans le traitement de maladies immunes
WO2017178416A1 (fr) 2016-04-15 2017-10-19 Bayer Animal Health Gmbh Dérivés de pyrazolopyrimidine
WO2017192385A1 (fr) 2016-05-05 2017-11-09 Elanco Tiergesundheit Ag Composés d'hétéroaryl-1,2,4-triazole et d'hétéroaryl-tétrazole pour lutter contre les ectoparasites
WO2019170626A1 (fr) 2018-03-08 2019-09-12 Bayer Aktiengesellschaft Utilisation de composés hétéroaryle-triazole et hétéroaryle-tétrazole en tant que pesticides dans la protection des plantes
WO2019197468A1 (fr) 2018-04-12 2019-10-17 Bayer Aktiengesellschaft Dérivés de n-(cyclopropylméthyl)-5-(méthylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]éthyl}benzamide et dérivés de pyridine-carboxamide correspondants utilisés en tant que pesticides
WO2019201835A1 (fr) 2018-04-17 2019-10-24 Bayer Aktiengesellschaft Composés hétéroaryle-triazole et hétéroaryle-tétrazole utilisés en tant que pesticides
WO2019206799A1 (fr) 2018-04-25 2019-10-31 Bayer Aktiengesellschaft Nouveaux composés hétéroaryle-triazole et hétéroaryle-tétrazole utilisés en tant que pesticides
WO2019215198A1 (fr) 2018-05-08 2019-11-14 Syngenta Crop Protection Ag Procédés d'application d'un ou de plusieurs composés d'hétéroaryl-1,2,4-triazole et d'hétéroaryl-tétrazole pour lutter contre des dommages sur des plantes, un matériau de propagation de celles-ci, et des produits dérivés de plantes
WO2020053364A1 (fr) 2018-09-13 2020-03-19 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020053365A2 (fr) 2018-09-13 2020-03-19 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020070049A1 (fr) 2018-10-02 2020-04-09 Syngenta Participations Ag Composés de benzène et d'azine-amide à action pesticide
WO2020079198A1 (fr) 2018-10-19 2020-04-23 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020094363A1 (fr) 2018-11-05 2020-05-14 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020169445A1 (fr) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Composés azole-amide à action pesticide
WO2020193341A1 (fr) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Dérivés de n-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)éthyl]-2-cyclopropyl-6-(trifluorométhyl)pyridine-4-carboxamide et composés apparentés servant d'insecticides
WO2020201398A1 (fr) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
WO2020201079A1 (fr) 2019-03-29 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
WO2020208036A1 (fr) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
WO2020212235A1 (fr) 2019-04-15 2020-10-22 Bayer Animal Health Gmbh Nouveaux composés d'aminoalkylazole à substitution hétéroaryle utilisés en tant que pesticides
WO2020219871A1 (fr) 2019-04-26 2020-10-29 Celgene Corporation Composés hétérocycliques et leur utilisation pour le traitement d'infections et de maladies helminthiques

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539588A1 (fr) 1990-07-05 1993-05-05 Nippon Soda Co., Ltd. Derive d'amine
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
WO1996029073A1 (fr) 1995-03-20 1996-09-26 Merck & Co., Inc. Derives de l'acide nodulisporique
US5595991A (en) 1995-03-20 1997-01-21 Merck & Co., Inc. Anthelmintic use of nodulisporic acid and analogs thereof
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US5834260A (en) 1996-08-30 1998-11-10 Merck & Co., Inc. Antiparasitic agents
US5945317A (en) 1996-08-30 1999-08-31 Merck & Co., Inc. Antiparasitic agents
WO2002085838A1 (fr) 2001-04-24 2002-10-31 Massachusetts Institute Of Technology Formation par catalyse de cuivre de liaisons carbone-heteroatome et carbone-carbone
US20050182059A1 (en) 2003-12-31 2005-08-18 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
US7361689B2 (en) 2003-12-31 2008-04-22 Schering-Plough Animal Health Corporation Antibacterial 1-(4-mono- and di-halomethylsulphonylphenyl)-2-acylamino-3-fluoroproponals and preparation thereof
US7312248B2 (en) 2004-09-23 2007-12-25 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives
US20060128779A1 (en) 2004-11-19 2006-06-15 Schering-Plough Animal Health Corporation Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1H-pyrrol-2-yl)acrylonitrile derivatives
US20060281695A1 (en) 2005-06-09 2006-12-14 Schering-Plough Animal Health Corporation Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives
WO2007115643A1 (fr) 2006-03-31 2007-10-18 Bayer Cropscience Ag Composés énaminocarbonylés substitués
WO2010053517A2 (fr) 2008-10-29 2010-05-14 Aroian Raffi V Polythérapie pour combattre une résistance aux helminthes
WO2010075591A2 (fr) 2008-12-24 2010-07-01 Praxair Technology, Inc. Procédé de réduction des émissions de dioxyde de carbone
WO2017106607A1 (fr) 2015-12-17 2017-06-22 Merck Patent Gmbh Antagonistes de tlr7/8 polycyliques et leur utilisation dans le traitement de maladies immunes
WO2017178416A1 (fr) 2016-04-15 2017-10-19 Bayer Animal Health Gmbh Dérivés de pyrazolopyrimidine
WO2017192385A1 (fr) 2016-05-05 2017-11-09 Elanco Tiergesundheit Ag Composés d'hétéroaryl-1,2,4-triazole et d'hétéroaryl-tétrazole pour lutter contre les ectoparasites
WO2019170626A1 (fr) 2018-03-08 2019-09-12 Bayer Aktiengesellschaft Utilisation de composés hétéroaryle-triazole et hétéroaryle-tétrazole en tant que pesticides dans la protection des plantes
WO2019197468A1 (fr) 2018-04-12 2019-10-17 Bayer Aktiengesellschaft Dérivés de n-(cyclopropylméthyl)-5-(méthylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]éthyl}benzamide et dérivés de pyridine-carboxamide correspondants utilisés en tant que pesticides
WO2019201835A1 (fr) 2018-04-17 2019-10-24 Bayer Aktiengesellschaft Composés hétéroaryle-triazole et hétéroaryle-tétrazole utilisés en tant que pesticides
WO2019206799A1 (fr) 2018-04-25 2019-10-31 Bayer Aktiengesellschaft Nouveaux composés hétéroaryle-triazole et hétéroaryle-tétrazole utilisés en tant que pesticides
WO2019215198A1 (fr) 2018-05-08 2019-11-14 Syngenta Crop Protection Ag Procédés d'application d'un ou de plusieurs composés d'hétéroaryl-1,2,4-triazole et d'hétéroaryl-tétrazole pour lutter contre des dommages sur des plantes, un matériau de propagation de celles-ci, et des produits dérivés de plantes
WO2020053364A1 (fr) 2018-09-13 2020-03-19 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020053365A2 (fr) 2018-09-13 2020-03-19 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020070049A1 (fr) 2018-10-02 2020-04-09 Syngenta Participations Ag Composés de benzène et d'azine-amide à action pesticide
WO2020079198A1 (fr) 2018-10-19 2020-04-23 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020094363A1 (fr) 2018-11-05 2020-05-14 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020169445A1 (fr) 2019-02-18 2020-08-27 Syngenta Crop Protection Ag Composés azole-amide à action pesticide
WO2020193341A1 (fr) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Dérivés de n-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)éthyl]-2-cyclopropyl-6-(trifluorométhyl)pyridine-4-carboxamide et composés apparentés servant d'insecticides
WO2020201079A1 (fr) 2019-03-29 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
WO2020201398A1 (fr) 2019-04-05 2020-10-08 Syngenta Crop Protection Ag Composés de diazine-amide à action pesticide
WO2020208036A1 (fr) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
WO2020212235A1 (fr) 2019-04-15 2020-10-22 Bayer Animal Health Gmbh Nouveaux composés d'aminoalkylazole à substitution hétéroaryle utilisés en tant que pesticides
WO2020219871A1 (fr) 2019-04-26 2020-10-29 Celgene Corporation Composés hétérocycliques et leur utilisation pour le traitement d'infections et de maladies helminthiques

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"The Pesticide Manual", 2018, BRITISH CROP PROTECTION COUNCIL PUBLICATIONS
BIOORG. MED. CHEM. LETT., vol. 22, 2012, pages 5222 - 5226
CHEM. PHARM. BULL., vol. 63, 2015, pages 341 - 353
CHEM. REV., vol. 111, 2011, pages 6557 - 6602
CHEMMEDCHEM, vol. 9, no. 4, 2014, pages 719 - 723
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
GENNARO: "Remington: The Science and Practice of Pharmacy", 1995, LIPPINCOTT WILLIAMS & WILKINS
PONTE ET AL., MOLECULAR PHARMACOLOGY, vol. 81, no. 4, 2012, pages 567 - 577
T. HIGUCHIV. STELLA: "Pro-drugs as Novel Delivery Systems", A. C. S. SYMPOSIUM SERIES, vol. 14

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11560388B2 (en) 2019-03-19 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic aza-benzothiophene and aza-benzofuran compounds
US11964977B2 (en) 2020-05-29 2024-04-23 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
WO2023073641A1 (fr) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Composés de pyrrolopyridazine anthelminthiques
WO2023208174A1 (fr) * 2022-04-28 2023-11-02 杭州普济远成生物医药科技有限公司 Inhibiteur de désubiquitinase et son utilisation
US11999742B2 (en) 2022-10-28 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Also Published As

Publication number Publication date
EP4077322A1 (fr) 2022-10-26
CN114846014A (zh) 2022-08-02
JP2023506303A (ja) 2023-02-15
BR112022012130A2 (pt) 2022-08-30
AU2020404100A1 (en) 2022-06-09
MX2022007671A (es) 2022-07-19
US20230110397A1 (en) 2023-04-13
CA3164104A1 (fr) 2021-06-24

Similar Documents

Publication Publication Date Title
WO2021122906A1 (fr) Composés anthelminthiques comprenant une structure d'azaindoles
AU2020406093A1 (en) Anthelmintic compounds comprising a quinoline structure
WO2022122988A1 (fr) Composés anthelminthiques comprenant une structure de thiénopyridine
EP4259606A1 (fr) Composés anthelminthiques comprenant une structure de pyridine
JP2019513776A (ja) ピラゾロピリミジン誘導体
JP5791725B2 (ja) Ｎ−ヘテロアリール化合物
KR20200020911A (ko) 새로운 아자퀴놀린 유도체
KR20190141725A (ko) 새로운 비시클릭 피라졸 유도체
AU2017248514B2 (en) Heteroaryl compounds with a-cyclic bridging unit
US9096599B2 (en) Spiroindoline compounds
CA2855001A1 (fr) Derives de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
US9598412B2 (en) Spiroindoline compounds for use as anthelminthics
WO2014039422A1 (fr) Dérivés d'isoxazoline spirocyclique pour le traitement des poux de mer
US20150223463A1 (en) Spirocyclic isoxazoline derivatives for treatment of sea lice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20833809

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3164104

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020404100

Country of ref document: AU

Date of ref document: 20201217

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2022537141

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022012130

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020833809

Country of ref document: EP

Effective date: 20220718

ENP Entry into the national phase

Ref document number: 112022012130

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220617